PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer (Registro nro. 22750)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03308nam a2200277 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | spa |
| 100 ## - Autor | |
| Autor | Agarwal, Neeraj |
| Rol del Autor | Autor |
| 9 (RLIN) | 53807 |
| 245 ## - Titulo | |
| Titulo | PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer |
| 300 ## - Páginas | |
| Paginación | páginas: 427-439 |
| 520 ## - Resumen | |
| Resumen | Background: A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival and overall survival, with the greatest benefit observed in the cohort with alterations in homologous recombination repair genes.<br/>Methods: In this ongoing, phase 3, double-blind trial assessing talazoparib in patients with metastatic androgen pathway modulation–sensitive [APMS] prostate cancer harboring alterations in homologous recombination repair genes, we randomly assigned patients in a 1:1 ratio to receive talazoparib at a dose of 0.5 mg plus enzalutamide at a dose of 160 mg once daily (talazoparib group) or placebo plus enzalutamide at a dose of 160 mg once daily (control group). Randomization was stratified according to disease status (new or relapsed), disease volume (high or low), and BRCA (vs. non-BRCA) mutation status. The primary end point was investigator-assessed imaging-based progression-free survival. The key secondary end point was overall survival. Results: A total of 300 patients were assigned to the talazoparib group and 299 to the control group. At 3 years, progression-free survival was 77% in the talazoparib group and 56% in the control group (hazard ratio for disease progression or death, 0.48; 95% confidence interval [CI], 0.36 to 0.65; P<0.001). In this interim analysis, overall survival at 3 years was 78% in the talazoparib group and 72% in the control group (hazard ratio for death, 0.77; 95% CI, 0.56 to 1.04). Serious adverse events were reported in 42% and 32% of the patients in the talazoparib group and the control group, respectively. In the talazoparib group, the most common adverse events were anemia, fatigue, and decreased neutrophil count, and the most common event of grade 3 or higher was anemia, reported in 51% of the patients; two treatment-related deaths occurred.<br/>Conclusions: Talazoparib added to enzalutamide led to significantly better imaging-based progression-free survival than placebo plus enzalutamide among patients with metastatic APMS prostate cancer harboring alterations in homologous recombination repair genes. Serious adverse events were more common with talazoparib plus enzalutamide than with placebo plus enzalutamide. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CANCER GENITOURINARIO |
| 9 (RLIN) | 53654 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | UROLOGÍA |
| 9 (RLIN) | 6502 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDADES DE LA PRÓSTATA |
| 9 (RLIN) | 53783 |
| 700 ## - Autor Personal | |
| Autor Personal | Matsubara, Nobuaki |
| 9 (RLIN) | 53808 |
| 700 ## - Autor Personal | |
| Autor Personal | Azad, Arun A. |
| 9 (RLIN) | 53809 |
| 700 ## - Autor Personal | |
| Autor Personal | Saad, Fred |
| 9 (RLIN) | 53810 |
| 700 ## - Autor Personal | |
| Autor Personal | Mateo, Joaquin |
| 9 (RLIN) | 53811 |
| 700 ## - Autor Personal | |
| Autor Personal | Jiang, Shusuan |
| 9 (RLIN) | 53812 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22638 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM005 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | SQB |
No hay ítems disponibles.